Diagnosis, Assessment, and Disease Monitoring

Develop and validate translatable biomarkers for their use in preclinical and clinical drug development...

Accelerate the development of the next generation CNS imaging ligands and biofluid molecular signatures...

Initiate development of imaging and/or fluid biomarkers to demonstrate target engagement for 5 novel therapeutic targets for AD...

Incorporate imaging and/or fluid biomarkers into Phase II (proof of concept) drug trials to provide proof of mechanism and/or evidence of target engagement as trials...

Incorporate imaging and/or fluid biomarkers into Phase III (pivotal) drug trials to select subjects and/or provide evidence of target engagement...

Initiate studies to develop minimally invasive biomarkers for detection of cerebral amyloidosis, AD and AD-related dementias pathophysiology.

Initiate studies to link peripheral blood-based molecular signatures and central imaging and CSF biomarkers.

Launch research programs to develop and validate sensitive neuropsychological and behavioral assessment measures...

Develop and test methods for the standardization of immunoassays and mass-spectrometry/single reaction monitoring assay...

Support systematic evaluation of AT(N) research framework across multi-ethnic populations

Expand the AT(N) framework

Develop diagnostic and prognostic algorithms for use in clinical trials and in clinical practice.

Develop research programs aimed at evaluating a variety of technologies for in-place monitoring of individuals at all stages of disease...

Continue to develop standard outcome measures to enable data comparisons across studies...

Embed wearable technologies as well as pervasive computing approaches in existing and new clinical research...

Support the development and commericialization of wearables that can increase rigor in measuring environmental exposures and intervention dosing...

Build end-to-end secure, high frequency data capture platforms to enable continuous monitoring of research participants...

Maintain an open-access national repository of evidence -based tools for cognitive assessment...

Launch programs on impact of diagnosis on individuals and families, to include individual response and social impacts.

Longitudinal antemortem LBD characterization

Detect cognitive impairment when a patient or relative voices a concern to health care providers.

Improving differential diagnosis of symptomatic cognitive impairment.

Develop diagnostics/biomarkers in asymptomatic individuals.

Determining the value of screening for clinically relevant cognitive impairment in the absence of a cognitive complaint.

Neuroimaging characterization of LBD

LBD biomarker development

Develop FTD biomarkers for diagnosis and disease progression.

Develop and validate longitudinally tracked noninvasive markers of key vascular processes related to cognitive and neurologic impairment.

Develop novel blood/CSF biomarkers or PET ligands for FTLD-tau, -TDP or -FUS during life

Biomarker and risk profiles for TDP-43

Improve tools for assessment of risks, preclinical characteristics, and costs among health disparities populations by leveraging existing data/cohorts, designing targeted studies, and using

Increase utilization of culturally- and linguistically-appropriate assessment tools within ongoing and newly generated studies of AD/ADRD and vascular health intervention trials.

Increase training of health professionals to meet the demand for cognitive impairment and dementia diagnosis, care, and need for human-based research.

Characterize the clinical phenotype of progressive dementia associated with TBI

Intervention studies to investigate reversible causes of dementia.